SecBot SecBot
8-K ·Filed Jul 28, 2026

RGEN

REPLIGEN CORP
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-318853
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and raised guidance signal accelerating bioprocessing demand and market share gains. The BioLife acquisition adds a high-margin, recurring-revenue cell therapy platform. Watch for integration updates and margin trajectory in coming quarters; the stock may re-rate higher if organic momentum continues.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$145.34
T+0 close · Jul 28, 2026 · via day close
Latest settled
+23.85%
T+60 · $180.01
Vs SPY
+19.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $145.34entry
  2. T+1 · 4mo ago −2.83%α −1.29% · $141.23
  3. T+5 · 3mo ago +1.18%α −1.09% · $147.06
  4. T+20 · 3mo ago +25.01%α +21.63% · $181.69
  5. T+60 · 26d ago +23.85%α +19.50% · $180.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS of $0.54, beating consensus by 20.4%. The company raised full-year 2026 guidance for organic revenue growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, while also announcing a definitive agreement to acquire BioLife Solutions, a strategic move into cell therapy consumables.

Key Financial Metrics

EPS
$0.54
est $0.45 · +20.0%
Revenue
$204.1M
est $201.4M · +1.4% · +12.0% YoY
Rating
strong beat
Guidance
$813M-$835M
raised
Free Cash Flow
$51.0M
Gross Margin
53.9%

Key Facts

  • Q2 2026 revenue $204M, +12% reported and +13% organic YoY
  • Adjusted EPS $0.54 vs consensus $0.45 (beat by 20.4%)
  • GAAP EPS $0.09 vs $0.26 YoY due to acquisition/amortization costs
  • Raised FY26 guidance: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09
  • Announced definitive agreement to acquire BioLife Solutions (cell therapy consumables)
  • Adjusted operating margin expanded to 16.7% from 12.0% YoY
  • Cash and marketable securities $810M at June 30, 2026

Financial Impact

Revenue growth of 12% YoY and adjusted EPS growth of 46% YoY; full-year guidance raised by ~$0.10 at midpoint

revenueadjusted EPSoperating marginguidance

Risk Factors

  • Integration risk from BioLife acquisition; potential dilution from stock issuance
  • GAAP EPS depressed by amortization and deal costs may cause confusion
  • Macro headwinds in biotech funding could slow customer orders

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-318853
Document: 0001193125-26-318853-index.html0001193125-26-318853
Document: 0001193125-26-318853.txt0001193125-26-318853
8-K Data (Synthetic)0001193125-26-318853

Track record

16 reports on RGEN

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.47% at T+60 after the Jul 22, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 4/10 Entry $178.94 Now $162.78 −9.03% settles Feb 5
  2. Oct 30, 202617d ago 8-K Neutral 5/10 Entry $176.94 Now $162.78 −8.00% settles Jan 28
  3. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  4. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $175.80 Now $162.78 −7.41% settles Jan 25
  5. Oct 15, 20264w ago Institutional Cluster Mixed 3/10 Entry $184.17 Now $162.78 −11.61% settles Jan 12
  6. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $167.22 Now $162.78 −2.66% settles Jan 4
  7. Oct 6, 20265w ago 8-K Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
  8. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
  9. Aug 24, 202611w ago S-4 Neutral 6/10 Entry $181.69 Now $162.78 −10.41% settles Nov 18
  10. Jul 28, 202615w ago 8-K Bullish 7/10 Viewing Entry $145.34 to $180.01 Now $162.78 +12.00% ▲ +23.85% +19.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 28, 2026